Zobrazeno 1 - 10
of 1 755
pro vyhledávání: '"ELIAS JABBOUR"'
Autor:
Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-24 (2024)
Abstract The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeutic targets and the development of corresponding novel targeted therapies. Since 2017, twelve agents have been approved
Externí odkaz:
https://doaj.org/article/3a838f9aa5f045b186539449d87c7e7e
Autor:
Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri, Tapan M. Kadia, Rebecca Garris, Guillermo Montalban Bravo, Kelly Chien, Elizabeth Shpall, Partow Kebriaei, Hagop M. Kantarjian
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/cb51845e37254d6d8ab98fdbb4b106f4
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-11 (2024)
Abstract Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and surviva
Externí odkaz:
https://doaj.org/article/f99125f2984241afbadebc05133b6a04
Autor:
Kashi Raj Bhattarai, Robert J. Mobley, Kelly R. Barnett, Daniel C. Ferguson, Baranda S. Hansen, Jonathan D. Diedrich, Brennan P. Bergeron, Satoshi Yoshimura, Wenjian Yang, Kristine R. Crews, Christopher S. Manring, Elias Jabbour, Elisabeth Paietta, Mark R. Litzow, Steven M. Kornblau, Wendy Stock, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Cheng Cheng, Shondra M. Pruett-Miller, Mary V. Relling, Jun J. Yang, William E. Evans, Daniel Savic
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Defining genetic factors impacting chemotherapy failure can help to better predict response and identify drug resistance mechanisms. However, there is limited understanding of the contribution of inherited noncoding genetic variation on inte
Externí odkaz:
https://doaj.org/article/50de02b6348449e7a1264f8dc70d8016
Publikováno v:
Cadernos Metrópole, Vol 26, Iss 59, Pp 377-400 (2023)
Resumo São inúmeros os indicadores demonstrando a robustez e a resiliência do processo de desenvolvimento chinês ao longo das últimas décadas. Porém, não é incomum perceber nas análises correntes o processo chinês somente como mais um caso
Externí odkaz:
https://doaj.org/article/925e1e9545c34526aaf779a493094f49
Autor:
Amber Gibson, Cesar Nunez, Lindsay Robusto, Brianna Kammerer, Miriam Garcia, Michael Roth, Rachna Sheth, Priti Tewari, Aline Hittle, Laurie Toepfer, Romeo Torres, Nicholas J. Short, Elias Jabbour, Nitin Jain, Branko Cuglievan, David McCall
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/7804a232cea14e4297e67a1ae4f9285b
Autor:
Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, Tapan Kadia, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Sanam Loghavi, Keyur Patel, Guilin Tang, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Ghayas C. Issa, Yesid Alvarado, Guillermo Montalban-Bravo, Abhishek Maiti, Hussein A. Abbas, Koichi Takahashi, Sherry Pierce, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Patients with relapsed acute myeloid leukemia (rAML) experience dismal outcomes. We performed a comprehensive analysis of patients with rAML to determine the genetic dynamics and survival predictive factors. We analyzed 875 patients with newly diagno
Externí odkaz:
https://doaj.org/article/933107ee2d9a47c0ad4b8d730636ebc4
Autor:
ELIAS JABBOUR, UALLACE MOREIRA
Publikováno v:
Brazilian Journal of Political Economy, Vol 43, Iss 3, Pp 543-563 (2023)
ABSTRACT Deep changes have taken place in China over the past ten years. The debate increasingly revolves around its new dynamics of accumulation, even questioning under which typology to frame the current Chinese model. In this paper, we propose to
Externí odkaz:
https://doaj.org/article/4195ca0b2759479eb6ed2074233bdb63
Autor:
Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Prithviraj Bose, Farhad Ravandi, Ricardo Delumpa, Regina Abramova, Guillermo Garcia-Manero, Michael Andreeff, Jorge Cortes, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-11 (2023)
Abstract Background Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedista
Externí odkaz:
https://doaj.org/article/ad7ca09609614d58a1b068a42eba3a40
Autor:
Hagop Kantarjian, Fadi G. Haddad, Nitin Jain, Koji Sasaki, Nicholas J. Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Yesid Alvarado, Tapan Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina Dabaja, Musa Yilmaz, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Farhad Ravandi, Elias Jabbour
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-12 (2023)
Abstract Background Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential blinatumomab to low-in
Externí odkaz:
https://doaj.org/article/b4f44ab39b2049e6b4e01db67dec5fb5